Phase 2 N=25 Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
HIV-1 Infection · HIV Infections
Primary: Percentage of Participants With Plasma HIV-1 RNA >50 — 12.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=943 Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools
HIV Infection
Primary: Determination of the Prevalence of R5 and X4-tropic Variants of HIV in HIV-infected Population in Russia — 123; 85; 114; 78 participants
Phase 2 N=97 Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
HIV Infections · Kidney Diseases
Primary: Mean Glomerular Filtration Rate by Iohexol Clearance at Week 52 — 37.0; 40.1 mL/min/1.73 m²
Phase 4 N=32 CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
HIV Infections
Primary: Differences in Gene Expression Profiles Obtained at Baseline and Week 4 and Week 24. — 1.44 -fold TNF downregulation
Early Phase 1 N=9 Autologous CD4 T-Cells in HIV (C34-CXCR4)
Hiv
Primary: The Number of Subjects With Treatment Related Adverse Events — 2; 1; 2 Participants
Phase 3 N=190 Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
HIV Infections
Primary: Change From Baseline in Human Immunodeficiency Virus (HIV-1) Viral Load (Ribonucleic Acid [RNA]) — -0.890; -1.194; -0.953; -0.604 log10 copies/mL
Phase 2 N=15 Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
HIV Infections
Primary: Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells — 0.58 Log-10 copies/10^6…
Phase 3 N=52 Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
HIV Infection · Cardiovascular Disease · Inflammation
Primary: Percent Change in FMD — 0.57; -0.05 percent change in FMD — p=0.17
Phase 3 N=601 Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
HIV Infections
Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.854; 4.861; 4.840 log10 copies/milliliter(log10 copies/mL)
N/A N=79 Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection
HIV-1
Primary: Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 3 — -1.10 copies/mL
Phase 3 N=474 Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
HIV Infections
Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.873; 4.840; 4.886 log10 copies/milliliter(log10 copies/mL)
Phase 3 N=562 Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
HIV
Primary: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure — 0.23; 0.43; 0.45 proportion of…
Phase 4 N=45 Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
HIV Infection
Primary: Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells) — 2.2; -0.7…
Phase 2 N=8 Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
Human Immunodeficiency Virus (HIV)
Primary: Primary Outcome Measure — 1; 2 Participants
Phase 3 N=32 Effects of Intensive cART During Acute/Early HIV Infection
Acute HIV Infection
Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…
Phase 1 N=9 Maraviroc in Patients With Moderate and Severe COVID-19
COVID
Primary: Rate of Completion — 7 Participants
N/A N=7 R5 Integrase Study in HIV-1 Naive Patients
HIV Infections
Primary: Viral Load — 4 Participants
Phase 4 N=44 A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
HIV Infections
Primary: Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen — 24; 89; 119; 566…
Phase 3 N=52 Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
HIV
Primary: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period — .64; .23; .36; .77…
Phase 3 N=917 Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
HIV-1
Primary: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic…
Phase 2 N=79 Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)
HIV · HIV Infections
Primary: Percentage of Participants With ≥1 Adverse Events (AEs) — 91 Percentage of Participants
Phase 2 N=13 Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
Human Immunodeficiency Virus
Primary: Number of Participants With Severe and Life-threatening Adverse Events (AEs) — 0; 4; 4; 0 Participants
Phase 2 N=37 Phase II Maraviroc for GVHD Prevention
Hematologic Malignancy
Primary: Day +180 Rate of Grade II-IV Acute GVHD — 22 Participants
Phase 4 N=38 FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
HIV-1 Infection
Primary: Change in Levels of CD8+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) From Baseline to Weeks 24 and 48 on ART — -4.01 % of CD8+ T-cells — p=0.001
Phase 2 N=30 Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
HIV-2 Infection
Primary: Percentage of Participants in Therapeutic Success — 40 percentage of participants
Phase 4 N=28 Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
HIV Infections
Primary: Change From Baseline in CD4 Count at 48 Weeks — 192; 205 cells/uL
Phase 2 N=116 Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)
HIV Infections
Primary: Change From Baseline in Log10 Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Week 48 of the Double-blind Period — 4.52; 4.50; 4.62; -1.78 Log10 copies/mL…
Phase 4 N=10 Maraviroc Efficacy for Hepatitis C
Hepatitis C · Human Immunodeficiency Virus
Primary: The Change in Hepatitis C Viral Load From Baseline to 4 Weeks of Maraviroc or No Maraviroc — 2035071; 2027648; 2082302; 1216383 International Units/ml — p=0.13
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
N/A N=18 Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Acute HIV Infection
Primary: Mean White Blood Cell Count Between Treatment Groups at 2 Months — 5904; 4918 white blood cells per microliter (mcL).